Chongqing Zhifei Bio Products (300122) — Net Asset Quality Index
Chongqing Zhifei Bio Products (300122) has a Net Asset Quality Index of 54.0% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥29.09 Billion minus total liabilities of CN¥13.38 Billion yields net assets of CN¥15.71 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check 300122 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Chongqing Zhifei Bio Products Net Asset Quality Index Over Time (2007–2025)
This chart shows how Chongqing Zhifei Bio Products's Net Asset Quality Index has evolved across 19 annual periods from 2007 to 2025. As of March 2026, the index stands at 54.0%, representing net assets of CN¥15.71 Billion against total assets of CN¥29.09 Billion CNY. See Chongqing Zhifei Bio Products working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Chongqing Zhifei Bio Products (2007–2025)
The table below presents the year-by-year Net Asset Quality Index for Chongqing Zhifei Bio Products from 2007 to 2025, covering 19 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Chongqing Zhifei Bio Products (300122) total market value.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 50.8% | CN¥16.11 Billion | CN¥31.72 Billion | CN¥15.61 Billion | ▼ -11.0 pp |
| 2024 | 61.8% | CN¥30.83 Billion | CN¥49.91 Billion | CN¥19.08 Billion | ▼ -0.9 pp |
| 2023 | 62.7% | CN¥31.51 Billion | CN¥50.23 Billion | CN¥18.73 Billion | ▼ -1.1 pp |
| 2022 | 63.8% | CN¥24.24 Billion | CN¥38.00 Billion | CN¥13.77 Billion | ▲ +5.0 pp |
| 2021 | 58.8% | CN¥17.66 Billion | CN¥30.05 Billion | CN¥12.39 Billion | ▲ +4.6 pp |
| 2020 | 54.2% | CN¥8.25 Billion | CN¥15.22 Billion | CN¥6.97 Billion | ▲ +1.7 pp |
| 2019 | 52.5% | CN¥5.75 Billion | CN¥10.94 Billion | CN¥5.20 Billion | ▼ -8.9 pp |
| 2018 | 61.4% | CN¥4.18 Billion | CN¥6.81 Billion | CN¥2.63 Billion | ▼ -10.2 pp |
| 2017 | 71.5% | CN¥2.94 Billion | CN¥4.11 Billion | CN¥1.17 Billion | ▼ -21.5 pp |
| 2016 | 93.1% | CN¥2.52 Billion | CN¥2.71 Billion | CN¥188.21 Million | ▲ +1.0 pp |
| 2015 | 92.1% | CN¥2.47 Billion | CN¥2.68 Billion | CN¥212.40 Million | ▲ +1.5 pp |
| 2014 | 90.5% | CN¥2.46 Billion | CN¥2.71 Billion | CN¥256.72 Million | ▼ -1.8 pp |
| 2013 | 92.3% | CN¥2.39 Billion | CN¥2.59 Billion | CN¥198.61 Million | ▼ -2.5 pp |
| 2012 | 94.8% | CN¥2.37 Billion | CN¥2.50 Billion | CN¥130.53 Million | ▲ +0.9 pp |
| 2011 | 93.9% | CN¥2.26 Billion | CN¥2.40 Billion | CN¥146.22 Million | ▼ -3.0 pp |
| 2010 | 96.9% | CN¥2.14 Billion | CN¥2.21 Billion | CN¥67.59 Million | ▲ +9.7 pp |
| 2009 | 87.2% | CN¥451.69 Million | CN¥518.02 Million | CN¥66.33 Million | ▲ +18.7 pp |
| 2008 | 68.5% | CN¥267.06 Million | CN¥390.10 Million | CN¥123.05 Million | ▲ +11.9 pp |
| 2007 | 56.6% | CN¥188.03 Million | CN¥332.30 Million | CN¥144.27 Million | — |